



Chair's Address for AGM

As you know, we are the global leader in MRI-compatible interventional devices, enabling physicians to fully utilize MRI's superior imaging during and throughout interventional procedures. Our initial focus has been cardiac ablation, a fast-growing, 10 billion US dollar annual market.

When we started Imricor, developing MRI-compatible ablation devices posed significant technical barriers. Only Imricor had the expertise to overcome them; and today, we remain the first—and only—company to deliver a full suite of MRI-compatible ablation tools for clinical use.

Achieving our vision meant inventing, developing, and gaining approval for nearly every device required for MRI-guided ablations—built on our proprietary and patented technology platform. While others have tried, only Imricor has succeeded. And the goal has always been clear: faster, safer, more effective procedures at lower cost.

Each regulatory approval we gain represents more than a single device—it's an entire platform: multiple consumables, capital equipment, and now, our MRI-native mapping and guidance system, NorthStar. We have secured approvals for our ablation devices across Europe and the Middle East, with NorthStar approvals expected soon. And we are currently advancing through the U.S. FDA process.

The most important news: the technology is already delivering outstanding clinical results. We are now scaling commercialization globally, and unlocking significant value for patients, physicians, hospitals, payers, and investors.

And cardiac ablation is just the beginning. New clinical applications are emerging rapidly. An MRI-guided biopsy tool is already in development. Opportunities in renal denervation, structural heart, oncology, neurology, and beyond are also coming into focus. On the software side, NorthStar is positioned to become the core navigation platform for MRI-guided interventions, and its future diagnostic use could unlock additional new markets.

In 2024, and including the current year so far, we've made excellent progress across many fronts.

We gained Saudi FDA approval and signed distributors in both the KSA and Qatar. We then followed that with our first sale in the region to our Qatar distributor. We are eagerly awaiting the registration of our 3rd party partner's RF generator in KSA, and we look forward to further accelerating adoption in the middle east.

In Europe, we gained CE mark approval under the new more stringent Medical Device Regulation (or MDR) for our Vision-MR Diagnostic Catheter, our 2nd generation Vision-MR Ablation Catheter (which includes two different curve sizes), and our new Advantage-MR EP Recorder/Stimulator system, which incorporates technology updates to match the 2nd generation ablation catheter. Now we are fully switched over to the MDR environment, which includes our



quality system, manufacturing processes, and so on. We've even had a couple of surprise on-site audits from our Notified Body, for which of course, the team is always well prepared.

We've also seen site activations (or in some cases re-activations) across Europe, including Amsterdam University Medical Centre in The Netherlands; Dubrava University Hospital in Zagreb Croatia; Lausanne University Hospital in Switzerland; and Semmelweis University's Heart and Vascular Centre, in Budapest Hungary.

Now with our European sales team fully resourced, we are once again building a pipeline of new sites and progressing our expansion across Europe. The anticipated CE mark approval of NorthStar is expected to help drive adoption, as is the progression of our VISABL-VT trial.

And speaking of trials, we advanced and received approvals to start both our VISABL-AFL trial (to support US FDA approval) and our VISABL-VT trial (to support expanded indications for the Vision-MR Ablation Catheter). We then began enrolling in the VISABL-AFL trial (which included the first procedure performed in the United States) while we (in parallel) began submitting modules to the FDA for review. The first module has been approved, and second module is currently in process.

And, of course, we commenced the VISABL-VT trial with our first roll-in patient at Amsterdam University Medical Centre, a procedure which included two first-in-human experiences of ablating in the ventricle and ablating on the left side of the heart inside an MRI. This was a huge milestone for the field, and we have been very fortunate to be able to partner with the dedicated, world class team from Amsterdam UMC on this important ground-breaking work.

Finally, I'd also like to say how fortunate we all are at Imricor to partner – in a very real sense – with all of you, our shareholders, as we aim to improve patient care and safety, decrease the cost of healthcare, and provide safer work environments for the medical personnel who dedicate their careers to caring for all of us. What we're doing is important, and the support we have seen from the investment community is vital to that work. That means we're all in this together. With our recent financing of 70 million Australian dollars, we have a balance sheet, now, that enables us to progress and accelerate toward our mission, and I want to personally thank you all.

I would also like to take a moment to thank and acknowledge team at Imricor. I am so fortunate to work with some of the best talent in the field. Living in the twin cities, with medical device giants like Medtronic, Abbott, and Boston Scientific, as well as countless start-ups, these are people who have choices about where they work, and it is a testament to the significance of what we're doing together that we are all so dedicated to our mission of growing interventional cardiac magnetic resonance to be a new standard of care.

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

For personal use only



About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and believes it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union, the Kingdom of Saudi Arabia (KSA), and New Zealand with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in the U.S. and the other Middle East countries.

The Company has also obtained approval within the EU and KSA for the sale of the Advantage-MR EP Recorder/Stimulator System and other consumable products, such as the Vision-MR Diagnostic Catheter (pending in KSA) and Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V., Siemens Healthcare GmbH, and GE HealthCare help to target certain sites and support the design and construction of iCMR labs for those sites.

Foreign Ownership Restrictions

Imricor's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.